Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7CNS 5Dermatologic 2Lymphoid 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 85pembrolizumab 76Magnetic Resonance Spectroscopy 46Radiotherapy, Intensity-Modulated 41Specimen Handling 36Cetuximab 36Carboplatin 35Radiotherapy 34Nivolumab 28Paclitaxel 24Radiation 22Platinum 22Docetaxel 20Biopsy 201,2-diaminocyclohexaneplatinum II citrate 20Gemcitabine 19Surveys and Questionnaires 15Fluorouracil 14toripalimab 13Standard of Care 12Taxes 11cemiplimab 9atezolizumab 9Ipilimumab 9Drug Therapy 9Cyclophosphamide 9X-Rays 8Surgical Procedures, Operative 8Radiosurgery 7Immunoglobulin G 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Transurethral Resection of Bladder × Head & Neck × 90 days × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡